Efficacy, safety and tolerability of rozanolixizumab in patients with chronic inflammatory demyelinating polyradiculoneuropathy: a randomised, subject-blind, investigator-blind, placebo-controlled, phase 2a trial and open-label extension study - Querol, Luis; De Sèze, Jérôme; Dysgaard, Tina; Levine, Todd; Rao, T Hemanth; Rivner, Michael; Hartung, Hans-Peter; Kiessling, Peter; Shimizu, Saori; Marmol, Dominika; Bozorg, Ali; Colson, Anny-Odile; et al. (Journal of neurology, neurosurgery and psychiatry, 2024)
Keywords: Adult; Aged; Antibodies, Monoclonal, Humanized - administration & dosage; Antibodies, Monoclonal, Humanized - adverse effects; Antibodies, Monoclonal, Humanized - therapeutic use; Antigens; Apheresis; Disease; FC RECEPTOR; Female; Humans; Immunoglobulins; Immunoglobulins, Intravenous - adverse effects; Immunoglobulins, Intravenous - therapeutic use; Male; Middle Aged; MOVEMENT DISORDERS; MYASTHENIA; Neuromuscular; Neuromuscular diseases; Patients; Polyradiculoneuropathy, Chronic Inflammatory Demyelinating - drug therapy; RANDOMISED TRIALS; Single-Blind Method; Treatment Outcome; Tuberculosis; RANDOMISED TRIALS; MOVEMENT DISORDERS; MYASTHENIA; FC RECEPTOR; NEUROMUSCULAR